Selection of Candidate Monoclonal Antibodies for Therapy of Botulinum Toxin Type A Intoxications
2024
Natalia A. Zeninskaya | Alena K. Ryabko | Maksim A. Marin | Tatyana I. Kombarova | Maria A. Shkuratova | Methun M. Rogozin | Marina V. Silkina | Yana O. Romanenko | Tatiana A. Ivashchenko | Igor G. Shemyakin | Victoria V. Firstova
Botulism is one of the most serious food intoxications, manifesting as prolonged paralytic conditions. This disease is usually the result of the consumption of poor quality canned or smoked foods, so the inhabitants of many countries of the world are exposed to the risk of this kind of poisoning every year. In view of the severity of poisonings caused by botulinum neurotoxins, monoclonal antibodies (mAbs) show great promise because of their targeting action, lack of allergic reactions and serum sickness. The use of a cocktail of mAbs increases the &ldquo:functional specificity&rdquo: of their mixture, allowing them to bind to the active domains of different toxin chains and block their action. In this work, we obtained 14 murine mAbs to the catalytic and receptor-binding domain of botulinum toxin type A. The Sp2/0-Ag14 murine myeloma cell line and splenocytes from immunized mice of the BALB/c line were used as fusion partners. We have shown that the selected cocktail of three antibodies neutralizes native toxin more effectively than antibodies separately&mdash:complete neutralization is achieved at a toxin dose of 3LD50 and partial neutralization at 5LD50. We presume that this cocktail may be promising as a prototype for the creation of a therapeutic drug capable of neutralizing the toxin in the blood of patients.
显示更多 [+] 显示较少 [-]